

Audited Financial Results for the Year ended 31st March 2016 (Standalone)

| PARTICULARS | (in ₹ Lacs, except equity share and per equity share data) | | | |
|--|--|--|--|---|
| | 3 months ended (31/03/2016) (Audited) | Preceding 3 months ended (31/12/15) (Un Audited) | Corresponding 3 months ended in the previous year (31/03/15) | Current Year ended (31/03/2016) (Audited) |
| 1. Income from Operations | | | | |
| (a) Net Sales / Income from Operations (Net of Excise Duty) | 2312 | 2789 | 2478 | 11260 |
| (b) Other Operating Income | 66 | 33 | 37 | 219 |
| Total Income from Operations (Net) (a+b) | 2378 | 2816 | 2515 | 11479 |
| 2. Expenses | | | | |
| a. Cost of Materials Consumed | 940 | 888 | 536 | 3520 |
| b. Purchase of Stock in Trade | 727 | 500 | 521 | 2361 |
| c. Changes in Inventories of Finished goods, work in progress & Stock in Trade | (24) | 28 | 234 | (73) |
| d. Employee Benefits Expense | 518 | 500 | 459 | 2065 |
| e. Depreciation and Amortisation Expense | 36 | 40 | 47 | 160 |
| f. Other Expenses | 791 | 803 | 654 | 3256 |
| Total Expenses | 2988 | 2759 | 2450 | 11288 |
| 3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items (1-2) | (610) | 57 | 65 | 192 |
| 4. Other Income | 55 | 55 | 45 | 125 |
| 5. Profit/(Loss) (from Ordinary activities before Finance Costs and Exceptional items (3-4) | (555) | 112 | 110 | 314 |
| 6. Finance Costs | (24) | 78 | 72 | 201 |
| 7. Profit/(Loss) from Ordinary activities after Finance Costs but before Exceptional Items (5-6) | (579) | 34 | 38 | 113 |
| 8. Exceptional Items | 0 | 0 | 0 | 0 |
| 9. Profit/(+)/Loss(-) from Ordinary Activities before Tax (7+8) | (579) | 34 | 38 | 113 |
| 10. Tax Expense | 0 | 0 | 0 | 67 |
| 11. Net Profit/(+)/Loss(-) from Ordinary Activities after Tax (9-10) | (579) | 34 | 38 | 46 |
| 12. Extraordinary Items (net of tax expense) | 0 | 0 | 0 | 0 |
| 13. Net Profit/(+)/Loss(-) for the period (11-12) | (579) | 34 | 38 | 46 |
| 14. Paid up equity share capital (Face Value '10/- each) | 116 | 116 | 116 | 116 |
| 15. Reserve excluding Revaluation Reserves | 1613 | 1669 | 1464 | 1570 |
| 16. Earning per share (in ₹) | (2.75) | 2.92 | 3.09 | 3.93 |
| a) Basic and Diluted before Extraordinary item | (2.75) | 2.92 | 3.09 | 3.93 |
| b) Basic and Diluted after Extraordinary item | (2.75) | 2.92 | 3.09 | 3.93 |

SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED

| PARTICULARS | (in ₹ Lacs) | | | |
|--|---|---|---|--|
| | Quarter ended 31st March 2016 (Audited) | Preceding Quarter ended 31st December 2015 (Un Audited) | Corresponding Quarter ended 31st March 2015 (Audited) | Current Year ended 31st March 2016 (Audited) |
| 1. Segment Revenue | | | | |
| a. Pharma | 2936 | 2848 | 2566 | 11567 |
| b. Furnishing | (3) | 23 | 4 | 35 |
| c. Unallocated | 0 | 0 | 0 | 0 |
| Total | 2933 | 2871 | 2566 | 11602 |
| Less: Inter Segment Revenue | 0 | 0 | 0 | 0 |
| Total Income | 2933 | 2871 | 2560 | 11602 |
| 2. Segment Results (Profit (+)/Loss (-) before tax and interest from each segment) | | | | |
| a. Pharma | (36) | 101 | 125 | 335 |
| b. Furnishing | (15) | 17 | (15) | (5) |
| c. Subsidiary | 0 | 0 | 0 | 0 |
| d. Unallocated | 0 | 0 | 0 | 0 |
| Total | (51) | 118 | 112 | 330 |
| Less: | | | | |
| i) Interest (net) | 24 | (78) | (72) | (201) |
| ii) Other Unallocable expenditure net of unallocable income | (3) | (5) | (2) | (15) |
| Total Profit/(Loss) before tax after extraordinary item | (31) | 34 | 38 | 115 |
| 3. Capital Employed (Segment Assets - Segment Liabilities) | | | | |
| a. Pharma | 1845 | 1763 | 1487 | 1845 |
| b. Furnishing | 37 | 150 | 183 | 37 |
| c. Subsidiary | 0 | 0 | 0 | 0 |
| d. Unallocated | (100) | 9 | (29) | (100) |
| Total | 1781 | 1922 | 1647 | 1781 |

Handwritten signature/initials

Summary of Assets & Liabilities as at 31st March 2016

| PARTICULARS | As at 31st March 2016 (Audited) | As at 31st March 2015 (Audited)(July 14 - March 15) |
|---|---------------------------------|---|
| A. EQUITY AND LIABILITIES | | |
| 1. Shareholder's Funds | | |
| (a) Share Capital | 116 | 116 |
| (b) Reserves and Surplus | 1570 | 1525 |
| (c) Money received against share warrants | | |
| 2. Non-Current Liabilities | | |
| (a) Long-term borrowings | 716 | 657 |
| (b) Deferred tax liabilities (Net) | 163 | 119 |
| (c) Other Long term liabilities | 324 | 308 |
| (d) Long term provisions | 41 | 43 |
| 3. Current Liabilities | | |
| (a) Short-term borrowings | 1634 | 1483 |
| (b) Trade payables | 2179 | 1708 |
| (c) Other current liabilities | 1043 | 752 |
| (d) Short-term provisions | 218 | 213 |
| TOTAL EQUITY AND LIABILITIES | 8003 | 6925 |
| B. ASSETS | | |
| 1. Non-current assets | | |
| (a) Fixed assets | | |
| (i) Fixed assets | 1841 | 1415 |
| (b) Non-current investments | 47 | 45 |
| (c) Long term loans and advances | 78 | 213 |
| (d) Other non-current assets | | |
| 2. Current assets | | |
| (a) Inventories | 1877 | 1944 |
| (b) Trade receivables | 2876 | 2339 |
| (c) Cash and cash equivalents & other bank balances | 98 | 52 |
| (d) Short-term loans and advances | 1992 | 838 |
| (e) Other current assets | 94 | 79 |
| TOTAL ASSETS | 8003 | 6925 |

| Particulars | NH |
|--|----|
| INVESTOR COMPLAINTS | |
| Pending at the beginning of the quarter | NH |
| Received during the quarter | 1 |
| Disposed of during the quarter | 1 |
| Remaining unresolved at the end of the quarter | NH |

Notes:
 1. The above financial results were taken on record by the Board of Directors in their Meeting held on 9th August, 2016
 2. The figures in respect of previous period have been regrouped/recast wherever necessary.

Place: Bengaluru
 Date : 9th August 2016

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

(Signature)
 (ABHAY KANORIA)
 CHAIRMAN & MANAGING DIRECTOR